On April 1, 2026, Bioscience Health Innovations, Inc. (the "Company") reported a significant change in its Board of Directors. Justin Earl has resigned from his position, effective immediately. The Company clarified that Mr. Earl's resignation was not due to any disagreements regarding the Company's operations, policies, or practices. In a swift response to this vacancy, the Board appointed Daniel Schmidt as a new director, also effective immediately. Mr. Schmidt has been with the Company since its inception, serving as the Chief Technology Officer. His extensive experience in therapeutic medical devices and treatments, including Radio Frequency, Stem Cells, Laser, and Ultrasound Technologies, positions him well to contribute to the Company's strategic direction. The Company emphasized its commitment to maintaining strong governance and operational execution as it navigates these leadership changes. This transition is expected to have a small positive impact on the stock price as the Company continues to leverage Mr. Schmidt's expertise in enhancing its product offerings and market position.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.